Optimisation Of Wolbachia Based Control Strategies To Reduce Dengue Incidence And Disease
Funder
National Health and Medical Research Council
Funding Amount
$6,073,640.00
Summary
The project will build on recent advances in the use of Wolbachia infected mosquitoes to limit dengue transmission. Key outcomes will include improved understanding of Wolbachia spread after release, development of techniques for regional spread, understanding the epidemiology of dengue transmission in Vietnam and preparing a panel of new Wolbachia:A. aegypti strain combinations for evaluation for implementation programs.
Dengue, Zika and Chikungunya are viral diseases transmitted to humans by mosquitoes. Our research uses a naturally-occurring bacteria, Wolbachia, to stop mosquitoes transmitting these viruses to humans. Our proposal addresses critical knowledge gaps in the biology of mosquitoes and Wolbachia to enable large-scale field-deployment optimisation in affected countries. The outcome of our research will immediately translate to disease control efforts in northern Australia, Asia and Latin America.
Central to improving the management of patients with cancer is an understanding of the molecular drivers of cancer. Based on our fundamental discoveries about the role of cell growth and perturbed cell signalling as drivers of cancer we will use the integration of molecular and imaging biomarkers with targeted therapies to translate this knowledge into better outcomes for cancer patients with defined molecular drivers of their cancer.
Generating The Evidence To Control Cancer And Optimise Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$6,564,341.00
Summary
Our Program addresses the public health aspects of common cancers, particularly cancers of the skin and gynaecological tracts. Each year in Australia, nearly 400,000 people are treated for skin cancer, and more than 3,500 women develop ovarian or uterine cancer. Our aims are first, to understand how we might prevent these cancers in the future; second, to enhance diagnosis of these cancers; and third, to improve the survival and quality of life for people who are diagnosed with these cancers